Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to boost immune attack on lung cancer

NCT ID NCT05570825

Recruiting now Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether combining two drugs, SX-682 and pembrolizumab, can shrink tumors in people with advanced non-small cell lung cancer that has spread or come back. The study will enroll 30 adults whose tumors have a certain protein (PD-L1) and who have not had prior treatment. The goal is to see if the combination improves the rate of tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SX-682 and pembrolizumab
What this could lead to
If this works, it could point toward a more effective treatment for advanced lung cancer by combining two drugs that boost the immune system against tumors.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The combination may cause side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC LUNG NON-SMALL CELL CARCINOMA RECURRENT LUNG NON-SMALL CELL CARCINOMA STAGE IIIC LUNG CANCER AJCC V8 STAGE IV LUNG CANCER AJCC V8

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.